Business Wire

PUMA

Share
PUMA Launches Major Brand Campaign to Strengthen Sports Performance Positioning

Global sports company PUMA has launched its first worldwide brand campaign in 10 years “FOREVER. FASTER. - See The Game Like We Do” with the objective to strengthen PUMA’s positioning as the Fastest Sports Brand in the world. The campaign conveys the brand’s unique connection with speed and invites everyone - professional and everyday athletes alike - to see the game like PUMA does.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240410842258/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Global sports company PUMA has launched its first worldwide brand campaign in 10 years “FOREVER. FASTER. - See The Game Like We Do” (Photo: Business Wire)

PUMA was founded in 1948 by Rudolf Dassler who had the vision to create shoes that make athletes agile, nimble and fast – just like a puma. Over the last 75 years, PUMA has worked with the fastest athletes, clubs and federations in the world to create cutting-edge innovations that provide sporting excellence and victories that live forever in the memories of fans across the globe.

This year – through the globally featured Brand Campaign - PUMA is demonstrating how speed has always been deeply rooted in the brand’s DNA. Speed has always been PUMA’s vantage point. The desire to be faster and overtake others is in everyone’s nature. To go faster gives you joy and an adrenaline rush like no other. The passion for speed is simply universal. “See The Game Like We Do: FOREVER. FASTER.” means to see sports and sports culture differently and ultimately win in a way only the fastest can. In a way only PUMA can. PUMA has always been able to be the first to see the next play, quick to act on its instinct, and set the pace for others to follow. This is what enables us to see the game differently, challenge conventions and create moments that will live with us forever.

“Everyone dreams of having a superpower and speed is PUMA’s,” said Arne Freundt, CEO of PUMA. “Speed is the superpower the greats use to change the game. Just like our world icons Mondo Duplantis, Karsten Warholm, Neymar Jr or Breanna Stewart, we know that speed unlocks athletic performance and victory in everyone. Through our ability to bring speed to life, PUMA invites all people to break through their own limits, unlock their personal best and become a better version of themselves, allowing them to see the game like we do: FOREVER. FASTER.”

“Our new global brand campaign is PUMA’s biggest marketing investment ever,” said Richard Teyssier, Vice President Brand and Marketing. “It is the first time that PUMA has one single message – FOREVER. FASTER. - throughout the entire year and across all performance categories such as Football, Running, Basketball and Handball. The holistic brand message is emotional and distinctive to make sure it connects and resonates with our target consumers.”

“FOREVER. FASTER. - See The Game Like We Do” launches on April 10 and will be communicated across the entire media mix, such as Social Media, TV, PR, Out Of Home Media and Points of Sale worldwide. It will include a hero brand film and supporting creative assets with featured top athletes, such as Antoine Griezmann, Breanna Stewart, Christian Pulisic, Felix Streng, Jack Grealish, Javier “Chicharito” Hernández, Karsten Warholm, Kai Havertz, Lamelo Ball, Luis Suarez, Memphis Depay, Mondo Duplantis, Neymar Jr., Sergio Aguero, Shericka Jackson, Yaroslava Mahuchikh and many others. Later this year, PUMA will present dedicated brand videos and creative assets for The CONMEBOL Copa America, UEFA Euro 2024, and The 2024 Summer Olympics.

Brand film, long version: https://youtu.be/LRJP140fv3E

Brand film, short version: https://youtu.be/OmQGUQNQkwk

Images: Link

PUMA

PUMA is one of the world’s leading sports brands, designing, developing, selling and marketing footwear, apparel and accessories. For 75 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs about 20,000 people worldwide, and is headquartered in Herzogenaurach/Germany.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240410842258/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 07:05:00 CET | Press release

L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additio

Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release

The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye